Page 28 - Layout 1
P. 28

MEDICAL YEAR
           IN REVIEW



        continued from page 27

        of medical marijuana with different propor-
        tions of various naturally occurring cannabi-
        noids  (primarily  THC  and  cannabidiol
        [CBD]) can be chosen to minimize its psy-
        choactive effects.
          Medical marijuana laws appear to have
        contributed to increased prevalence of il-
        licit cannabis use and cannabis use disor-
        ders; state-specific policy changes may also
        have played a role. While medical mari-
        juana  may  help,  some  cannabis-related
        health  consequences  associated  with
        changes in state marijuana laws should re-
        ceive consideration by health care profes-
        sionals and the public. (ref 5-8)


        Summary
          In summary, this is an area where doc-
        tors as lifelong learners will continue to
        see new information but are awaiting evi-
        dence-based recommendations.  We will
        likely take a back seat to dispensary “baris-
        tas”  and  our  patients’  experiences  but
        should keep eyes on the literature to man-
        age abuse, treat overdosage and use of
        adulterated  products,  and  recommend
        new therapies when available.


          J.J. Seidenfeld, MD is board certified in Pul-
        monary Disease and Internal Medicine and is a
        member of  the Bexar County Medical Society.


         References
        1. J  Basic  Clin  Physiol  Pharmacol  2016:  Therapeutic Target. Kaur R , Ambwani  US Adult Illicit Cannabis Use, Cannabis
           27(3): 181-7. Cannabis- the Israeli Per-  SR, Singh S. Department of Pharmacol-  Use  Disorder,  and  Medical  Marijuana
           spective. Mechoulam, R              ogy, AIIMS, Jodhpur, Rajasthan, India.  Laws 1991-1992 to 2012-2013 Deborah
        2. CMAJ. 2019 August 19:191:E907-8 doi  sidhurimple@yahoo.com. Abstract     S. Hasin, PhD; Aaron L. Sarvet, MPH;
           10.1503. Medical Cannabis: strengthen-  5. Epilepsia. 2014; 55(6):791-802. Doi:10-  Magdalena Cerdá, DrPH; Katherine M.
           ing  evidence  in  the  face  of  hype  and  1111. Cannabidiol. Pharmacology and  Keyes, PhD; Malka Stohl, MS; Sandro
           public pressure. Fitzcharles, MA, Shir,  potential role in epilepsy. Devinsky, O,  Galea, MD, DrPH; Melanie M.Wall, PhD
           Yoram, Hauser, Winfried             Cilio MR, Cross, H et al             Published online April 26, 2017.
        3. Ann  Med.  2016;48(3):128-41.  doi:  6. Current Medical Diagnosis and Treat-  8. Cannabis | The Substance Abuse Hand-
           10.3109/07853890.2016.1145794. Epub  ment  2020.  Maxine  A.  Papdakis  and  book, 2e | Pedro Ruiz and Eric C. Strain.
           2016 Feb 25. Cannabinoids: Medical im-  Stephen  J.  McPhee  15-02:  Nausea  &  Chapter One
           plications. Schrot RJ1,2, Hubbard JR3,4  Vomiting Kenneth R. McQuaid
        4. Curr Clin Pharmacol. 2016;11(2):110-7.  7. JAMA  Psychiatry.  2017;74(6):579-588.
           Endocannabinoid System: A Multi-Facet  doi:10.1001/jamapsychiatry.2017.0724

         28  San Antonio Medicine   •  December  2019
   23   24   25   26   27   28   29   30   31   32   33